67 reports

THESE INCLUDE TECHNOLOGIES FOR GENOME SEQUENCING, GENOME EDITING AND OTHER MOLECULAR-LEVEL CELL MANIPULATION SYSTEMS, SUCH AS SWITCHES AND TRANSPOSONS.

  • Leukemia
  • Company
  • Market Size
  • Juno Therapeutics Inc.
  • Novartis AG

THE COMPANY ALSO ANNOUNCED THAT IT RECEIVED POSITIVE OPINION GRANT FROM THE EUROPEAN CHMP FOR VIEKIRAX AND EXVIERA FOR THE TREATMENT OF PREVIOUSLY UNTREATED ADULT PATIENTS WITH GENOTYPE ##B (GT##B) CHRONIC HEPATITIS C VIRUS AND MINIMAL TO MODERATE FIBROSIS.

  • Leukemia
  • North America
  • United States
  • Ablynx NV
  • Amgen Inc.
  • Epidemiologist Insight

However, there is no current consensus on the specific genotypes used in treatment stratification; different combinations of favorable and unfavorable genotypes have been used to direct therapy, with substantial change in the genotypes considered significant over time.

  • Leukemia
  • Amgen Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.

However, these products may be useful in niche patient subgroups: quizartinib, for example, is able to elicit a response in patients with a FLT##-ITD mutant genotype.

  • Cancer
  • Leukemia
  • Therapy
  • Product Initiative
  • 8. References

Overexpression of CD## correlates with the hyperdiploid genotype in acute lymphoblastic leukemia Haematologica 2009; ##: ##-## (online access to paper) Du W, Li J, He Y et al.

  • Leukemia
  • United States
  • Cellectis S.A.
  • Janssen Biotech, Inc.
  • Kyowa Hakko Kirin Co., Ltd.

Seven patients received PEG-IFN (## microgms, ## patients; ## micrograms, ## patient; ## micrograms, ## patients) and two patients received Roferon-A (## MIU, ## patient; ## MIU, ## patient).

  • Blood Disease
  • Leukemia
  • Therapy
  • United States
  • Product Initiative

Similarly, the Universities' portfolio in Phase II, Phase I and Preclinical stages comprises ##, ## and ## molecules, respectively.

  • Cancer
  • Leukemia
  • United States
  • Product Initiative
  • Pfizer Inc.

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## ## ## Astellas Pharma Inc ## ## ## ## ## ## ## ## Takeda Pharmaceutical Co Ltd ## ## ## ## ## ## ## ## Incyte Corp ## ## ## ## ## ## ## ## Bellicum Pharmaceuticals Inc ## ##

  • Leukemia
  • Monoclonal Antibody
  • Pharmaceutical
  • United States
  • World

IT ACTS BY TARGETING PARP ## AND ## AND TANKYRASE ## AND ##.

  • Cancer
  • Leukemia
  • Therapy
  • United States
  • Product Initiative

THE INCOMING OF TECHNOLOGY DEVELOPERS FOR GENOME SEQUENCING, GENOME EDITING AND OTHER MOLECULAR SYSTEMS SUCH AS SWITCHES AND TRANSPOSONS, HAVE ACTED AS AN IMPETUS TO THE EFFORTS BEING MADE BY SEVERAL OTHER PARTICIPANTS IN THE T-CELL THERAPY INDUSTRY.

  • Leukemia
  • North America
  • United States
  • Juno Therapeutics Inc.
  • Kite Pharma, Inc.
  • TIPIFARNIB - DRUG PROFILE

The trial was registered with the U. S National Institutes of Health. ##-Feb-2016 PharmaEssentia Corporation announced that results from Phase II trial of P## plus ribavirin in patients with chronic HCV genotype ## infection will be presented by Prof.

  • Cancer
  • Leukemia
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • TG-02 - Drug Profile

Importantly, the mechanism of action for TG## functions independently of p## status, which could provide benefit to patients with poor prognosis genotypes that are resistant to many standard-of-care drugs.

  • Leukemia
  • Therapy
  • United States
  • Product Initiative
  • Cyclacel Pharmaceuticals, Inc.

In October, 2011 PharmaEssentia Corporation has initiated a open-label, randomized, active control study to evaluate the antiviral activity, safety and pharmacokinetics of P## plus ribavirin in treatment-naïve subjects with HCV genotype ## infection.

  • Leukemia
  • Lung Cancer
  • United States
  • Product Initiative
  • Incyte Corporation

The prominent features of this report are - ##.

  • Blood Disease
  • Chemotherapy
  • Leukemia
  • World
  • Product Initiative

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Hospital
  • Leukemia
  • Targeted Therapy
  • Therapy
  • Product Initiative

Importantly, the mechanism of action for TG## functions independently of p## status, which could provide benefit to patients with poor prognosis genotypes that are resistant to many standard-of-care drugs.

  • Cancer
  • Leukemia
  • Pharmaceutical
  • Therapy
  • Cyclacel Pharmaceuticals, Inc.

The trial was registered with the U. S National Institutes of Health. ##-Feb-2016 PharmaEssentia Corporation announced that results from Phase II trial of P## plus ribavirin in patients with chronic HCV genotype ## infection will be presented by Prof.

  • Blood Disease
  • Leukemia
  • United States
  • Product Initiative
  • Incyte Corporation
  • TG-02 - DRUG PROFILE

Importantly, the mechanism of action for TG## functions independently of p## status, which could provide benefit to patients with poor prognosis genotypes that are resistant to many standard-of-care drugs.

  • Leukemia
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation

In October 2008, Dynavax Technologies Corporation initiated a Phase I study to evaluate four dose levels of SD-## in ## chronically infected, treatment-naïve, genotype ## HCV patients was initiated.

  • Leukemia
  • Lymphoma
  • Oncology
  • Therapy
  • Celgene Corporation

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Blood Disease
  • Clinical Trial
  • Leukemia
  • World
  • GlaxoSmithKline plc
  • DIAGNOSTIC ASSAY - MRD IN LEUKEMIA - PRODUCT DESCRIPTION

Core operating income was USD ##. ## billion (-##%, +##% cc).

  • Clinical Trial
  • Leukemia
  • Therapy
  • United States
  • Pfizer Inc.

Radiographic tumor reductions were observed in ## of ## evaluable patients, including patients with complex genotypes involving primary and secondary KIT mutations.

  • Leukemia
  • Lymphoma
  • Pharmaceutical
  • Therapy
  • Merck & Co., Inc.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • Leukemia
  • Monoclonal Antibody
  • United States
  • World
  • Product Initiative
  • TG-02 - DRUG PROFILE

Importantly, the mechanism of action for TG## functions independently of p## status, which could provide benefit to patients with poor prognosis genotypes that are resistant to many standard-of-care drugs.

  • Leukemia
  • Therapy
  • United States
  • Product Initiative
  • Incyte Corporation

The automation provided by Analytik Jena promises ultra-high throughput genotyping, scaling from several hundred thousand to ## million samples per year.

  • Cancer
  • Healthcare
  • Leukemia
  • Corporate Finance
  • Illumina, Inc.
  • 5. All the trials included are unique trials.

Plenary Presentation Late-Breaking QuANTUM-R Data (Featured in Plenary Session ##): Oral Presentation, Plenary Session ##: Saturday, June ##, ##:## - ##:## PM CEST, Stockholmsmässan, room A##.

  • Blood Disease
  • Clinical Trial
  • Leukemia
  • Therapy
  • World
  • 5. All the trials included are unique trials.

Plenary Presentation Late-Breaking QuANTUM-R Data (Featured in Plenary Session ##): Oral Presentation, Plenary Session ##: Saturday, June ##, ##:## - ##:## PM CEST, Stockholmsmässan, room A##.

  • Clinical Trial
  • Leukemia
  • Monoclonal Antibody
  • World
  • Celgene Corporation

Oral Presentations LentiGlobin Gene Therapy for Transfusion-Dependent ß-Thalassemia (TDT) in Patients with Non-ß##/ ß## Genotypes: Updated Results from Northstar-## (Abstract S##) Presenter: Franco Locatelli, M. D., Ospedale Pediatrico Bambino Gesù, Rome, ItalyDate & Time:Saturday, Jun

  • Clinical Trial
  • Drug Development
  • Leukemia
  • Monoclonal Antibody
  • Celgene Corporation

Oral Presentations LentiGlobin Gene Therapy for Transfusion-Dependent ß-Thalassemia (TDT) in Patients with Non-ß##/ ß## Genotypes: Updated Results from Northstar-## (Abstract S##) Presenter: Franco Locatelli, M. D., Ospedale Pediatrico Bambino Gesù, Rome, ItalyDate & Time:Saturday, Jun

  • Clinical Trial
  • Drug Development
  • Leukemia
  • Monoclonal Antibody
  • Celgene Corporation

Lung Cancer PD-##/ PDL-## COMPANION DIAGNOSTIC ASSAY - LUNG CANCER PD-##/ PDL-## COMPANION DIAGNOSTIC ASSAY - LUNG CANCER PRODUCT OVERVIEW PD-##/ PDL-## COMPANION DIAGNOSTIC ASSAY - LUNG CANCER - PRODUCT STATUS PD-##/ PDL-

  • Cancer
  • Leukemia
  • Lung Cancer
  • Therapy
  • United States